Secondary prevention for acute coronary syndrome in rural South Australia: Are drugs best? What about the rest?

TM Wachtel¹, AM Kucia², JA Greenhill¹

¹Flinders University School of Nursing & Midwifery, Flinders University Rural Clinical School, Renmark, South Australia, Australia
²The University of South Australia, North Terrace, Adelaide, South Australia, Australia

Submitted: 17 March 2008; Resubmitted: 25 August 2008; Published: 14 October 2008

Wachtel TM, Kucia AM, Greenhill JA

Secondary prevention for acute coronary syndrome in rural South Australia: Are drugs best? What about the rest?

Rural and Remote Health 8: 967. (Online), 2008

Available from: http://www.rrh.org.au

ABSTRACT

Introduction: Acute coronary syndrome (ACS) is a major cause of morbidity and mortality worldwide. Current Australian clinical guidelines recommend all patients with ACS receive comprehensive secondary prevention services to address this burden. Optimal patient outcomes rely on the timely and effective implementation of proven therapies and for secondary prevention to be successful, pharmacological interventions must be combined with cardiovascular disease (CVD) risk factor identification and management. The ability to implement clinical guidelines is also reliant on available resources, yet many rural populations in Australia do not have access to structured secondary prevention services, and the level of support available to them in the form of unstructured services is unclear. Our aim was to examine the scope of secondary prevention in a ‘significantly restricted’ rural region of South Australia that does not have access to structured secondary prevention services.
Methods: A retrospective analysis of medical records was undertaken to identify documented evidence of assessment and intervention for medical, lifestyle and behavioural CVD risk factors in hospital and at follow up in general practice (GP) clinics. Eligible participants were patients admitted to hospital in the Riverland Region of South Australia with myocardial infarction over a 12 month period. Of 77 eligible participants, permission was received to access the medical records of 55 patients in the hospital setting, and 34 of these 55 patients in GP clinic follow up.

Results: Most patients received baseline assessment for previous AMI (98%), history of hypertension (82%), history of diabetes (78%), and smoking status (76%). Most poorly documented was history of dyslipidaemia (53%) and obesity/overweight (2%). Prescribing rates for recommended ACS medications at the time of hospital discharge were aspirin (90%), beta blockers (55%), ACE inhibitors (42%), lipid lowering medication (66%) and clopidogrel (64%). Overall prescribing rates in the 12 month study period rose to 80% or higher for all recommended medications. There was no evidence of interventions for smoking and obesity/overweight in the hospital setting and 45% of smokers in the GP clinic setting received quit advice. Measurement of biomedical risk factors (blood lipid analysis and blood glucose levels) was suboptimal, and there was no evidence of a written action plan for chest pain for any participants.

Conclusions: Unstructured services provided some of the recommended elements of secondary prevention. However, deficits in care exist that have the potential to negatively impact patient outcomes in this already disadvantaged population. Future research needs to focus on the extent to which this and other rural and remote health care services are working within current clinical guidelines for the management of ACS, and subsequent patient outcomes. Urgent consideration must also be given to the introduction and evaluation of a more structured and consistent approach in this and other rural and remote regions of Australia. The development of rehabilitation and prevention services that build on existing strengths and resources have the potential to widen access, enhance current services and ensure care is based on best practice guidelines. This in turn may reduce the burden of CVD and improve the overall health and quality of life for patients in rural and remote Australia.

Key words: acute coronary syndrome, cardiovascular disease, secondary prevention.

Introduction

Acute coronary syndrome (ACS) includes a range of cardiac conditions including acute myocardial infarction (AMI) and angina. Acute coronary syndrome is a major cause of morbidity and mortality and represents one of the most common causes of acute medical admissions in Australia. Current Australian clinical guidelines recommend all patients with ACS should receive secondary prevention services that aim to maximise physical, psychological and social functioning, and enable people with ACS to lead fulfilling and productive lives.

A comprehensive approach to secondary prevention should include a combination of pharmacological interventions (eg antiplatelet agents, beta-blockers, angiotensin-converting enzyme inhibitors, lipid lowering medications and nitrates) and lifestyle and behavioural interventions. This approach has been shown to significantly reduce the risk of future cardiac events and deaths, and leads to fewer readmissions to hospital, a shorter associated length of stay, and enhanced medication management. The National Heart Foundation Australia advocates a multidisciplinary approach to secondary prevention that includes nurses, doctors, physical therapists, dieticians, social workers and pharmacists working together to deliver therapeutic interventions and health behaviour advice for smoking cessation, physical inactivity, obesity, poor nutrition, high risk alcohol consumption, hypertension and dyslipidaemia. In this case secondary prevention specifically aims to impact on cardiac risk factors and this differs from a primary prevention approach, which employs population health activities aimed at health promotion and disease prevention whereby it is more difficult to directly attribute impacts of primary healthcare activities and initiatives.
Optimal patient outcomes rely on the timely and effective implementation of proven therapies\(^1\). Clinical guidelines for the management of ACS are readily available and are based on rigorous evidence\(^1\). However, the ability to implement these guidelines is dependent on the resources available in a particular region\(^1,12\). Rural and remote populations have a significantly higher incidence of cardiac mortality and morbidity than those in metropolitan areas\(^2,11\), yet they have poorer access to structured secondary prevention programs\(^14,15\) and are prescribed cardiovascular medications at half the rate of people living in major cities\(^13\).

The Riverland region of South Australia is a 3 hour drive north east of state capital Adelaide with a population of just under 35 000 people\(^16\). Cardiac related health services, including ad hoc secondary prevention, are provided by five hospitals and seven GP clinics in the region. In addition, patients have access to five visiting cardiologists who consult at the Riverland Regional Hospital’s Berri Campus and the Loxton District Hospital (three consult monthly and two consult bi-monthly). Patients are also required to travel to Adelaide for additional services, including admission to a metropolitan hospital for percutaneous coronary interventions and cardiac surgeries, and for cardiologist review if they are referred to specialist who does not consult in the Riverland\(^17\).

With a Socio Economic Index for Areas rating (SEIFA) of 961, the Riverland Region is placed 0-5% below the non-metro average in terms of socio-economic disadvantage\(^18\). An Accessibility/Remoteness Index of Australia (ARIA) rating of 3.6301–4.5262 classifies the Riverland as ‘moderately accessible’, or significantly restricted with regards to accessibility of goods, services and opportunities for social interaction\(^16,18,19\). This is significant due to the strong link between lower socioeconomic status and increased rates of cardiovascular disease (CVD) mortality\(^18\). The rate of CVD in the Riverland is well above the state average and is the primary killer in the region, accounting for nearly one-fifth of the total mortality burden\(^16\). Despite this high risk profile, there is currently no structured approach in the Riverland to secondary prevention, including cardiac rehabilitation, for patients with ACS.

Methods

Study design and data collection tool

A retrospective medical records analysis was undertaken to examine assessment of CVD risk factors and documented evidence of secondary prevention interventions within a 12 month time period. Medical record review has been used previously in Australia\(^20,21\), and internationally by the EUROASPIRE II study\(^22\) and GRACE study\(^23\) to collect demographic and CVD risk factor data, and pharmacological interventions for CVD. The data abstraction tool, initially developed to evaluate an outpatient, hospital-based cardiac rehabilitation program in the USA\(^24\), was adapted for the current study to encompass current ‘Australian Clinical Guidelines for the Management of Acute Coronary Syndromes’\(^1,4\). Data were pooled prior to analysis to preserve health service and patient anonymity.

Study participants and ethics approval

All patients admitted to hospital in the Riverland region between 1 July 2004 and 30 June 2005 with a primary diagnosis of AMI were eligible for inclusion in the study. Approval for the study was granted by the University of South Australia Human Research Ethics Committee.

The current study was undertaken in two separate phases.

Phase 1: The aim of phase 1 was to examine baseline assessment of CVD risk factors and implementation of current clinical guidelines for secondary prevention of ACS in the hospital setting. Permission
to access medical records of eligible patients \( (n = 77) \) was sought from all five Riverland hospitals (Fig1). Three hospitals agreed \( (n = 48) \), and the internal ethics committees of the remaining two hospitals consented, providing the hospitals contacted eligible patients and obtained individual consent. The hospitals sent a written invitation to participate in the study to 29 patients, 7 of whom responded and consented (24% response rate). The medical records of 55 of a possible 77 (71%) patients were accessed in the hospital setting.

Phase 2: The aim of phase 2 was to examine follow-up care and the implementation of current clinical guidelines for secondary prevention of ACS in the GP clinic setting for the 55 patients in phase 1. All seven GP clinics in the region were approached for permission to access the medical records of those same 55 patients. Five GP clinics granted access to relevant medical records, one of which required the researcher to gain written consent from each patient. Two GP clinics did not allow access to medical records. A total of 34 of a possible 55 medical records were accessed in the GP clinic setting (Fig2). Of the 21 records not accessed; five patients attended GP clinics that declined participation in the study, two patients were not Riverland residents, five patients died prior to follow up, and nine patients did not provide written consent.

Data collection

Categories in the data collection tool were: demographics, prescribed medications, previous AMI, biomedical risk factors (diabetes, hypertension, dyslipidaemia), and lifestyle and behavioural risk factors (obesity or overweight, physical activity, independence with activities of daily living, dietary habits, alcohol consumption, smoking status, living arrangements and social support).

Entries in the medical records were examined from the initial date of admission through to 12 months post-admission. Demographic and baseline CVD risk assessment data were collected in the hospital setting. Documented evidence of secondary prevention interventions, measurement of biomedical CVD risk factors, and deaths were collected in both the hospital and GP clinic setting.

Statistical analysis

Data were entered by hand on to the data abstraction tool and then entered into Microsoft Excel spreadsheets for analysis. Descriptive statistical analysis was used to calculate frequencies, mean values and range. Pharmacological and medical interventions in the current study refers to the assessment and measurement of biomedical risk factors, smoking and overweight/ obesity, referral to relevant health services, prescribing of recommended medications and the provision of a written action plan for chest pain.

Results

Demographic characteristics

The mean age was 68.2 years \( (+/-15.5 \text{ SD}) \), and 43 patients (78%) were male. Forty-five patients (82%) were born in Australia, and one patient (2%) was of Aboriginal or Torres Straight Islander decent. Demographic data is presented (Table 1).

Baseline assessment of biomedical risk factors, smoking and obesity in the hospital setting

The majority of patients were assessed for previous AMI and history of biomedical risk factors in the hospital setting, as depicted (Table 2). The most poorly documented risk factor was obesity/overweight, with only one patient (2%) diagnosed as obese (GP entry on admission form). While 22 patients (40%) were weighed during hospital admission, there was no evidence of body mass index (BMI) assessment or waist circumference measurement for any patient in the study. Also poorly documented was a history of dyslipidaemia with only 29 patients (53%) assessed in this category.
Figure 1: Phase One - hospital response rates and number of medical records accessed in the hospital setting. MR, Medical records.

Figure 2: Phase 2 - GP clinic response rates and number of medical records accessed in GP clinic setting. F/U, Follow up; MR, medical records; Pt, patient.
Table 1: Demographic characteristics of patients (n = 55) assessed in the hospital setting

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Yes n (%)</th>
<th>No n (%)</th>
<th>ND n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age</td>
<td>68.2 (+/- 15.6 SD)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Male</td>
<td>43 (78)</td>
<td>12 (22)</td>
<td>0</td>
</tr>
<tr>
<td>Australian born</td>
<td>45 (82)</td>
<td>8 (15)</td>
<td>2 (3)</td>
</tr>
<tr>
<td>ATSI decent</td>
<td>1 (2)</td>
<td>51 (93)</td>
<td>3 (5)</td>
</tr>
<tr>
<td>English first language</td>
<td>16 (29)</td>
<td>3 (5)</td>
<td>36 (66)</td>
</tr>
<tr>
<td>Past history of AMI</td>
<td>11 (20)</td>
<td>43 (78)</td>
<td>1 (2)</td>
</tr>
</tbody>
</table>

AMI, Acute myocardial infarction; ATSI, Aboriginal and/or Torres Straight Islander decent; ND, not documented.

Table 2: Baseline assessment of biomedical and behavioural risk factors in the hospital setting (n = 55)

<table>
<thead>
<tr>
<th>Category</th>
<th>Yes n (%)</th>
<th>No n (%)</th>
<th>ND n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous acute myocardial infarction</td>
<td>11 (20)</td>
<td>43 (78)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>History of hypertension</td>
<td>53 (60)</td>
<td>12 (22)</td>
<td>10 (18)</td>
</tr>
<tr>
<td>History of dyslipidaemia</td>
<td>19 (35)</td>
<td>10 (18)</td>
<td>26 (47)</td>
</tr>
<tr>
<td>History of diabetes</td>
<td>16 (29)</td>
<td>27 (49)</td>
<td>12 (22)</td>
</tr>
<tr>
<td>Diagnosis obesity/ overweight</td>
<td>1 (2)</td>
<td>0</td>
<td>54 (98)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>16 (29)</td>
<td>26 (47)</td>
<td>13 (24)</td>
</tr>
</tbody>
</table>

ND, not documented.

Pharmacological and medical interventions

The proportion of patients referred to additional health services by hospitals and GP clinics was 89% and 62%, respectively. The most common referral in the hospital setting was to a metropolitan hospital (67%), and the most common referral in the GP clinic setting was for review by a cardiologist (62%). Six patients (11%) in the hospital setting and 10 patients (29%) in the GP clinic setting were not referred to any additional health services.

There was no evidence of interventions for smoking or obesity/overweight in the hospital setting. In the GP clinic setting, five of 11 smokers (45%) received ‘quit’ advice and one smoker was prescribed nicotine replacement therapy. Sixteen of 34 patients (47%) followed up in the GP clinic setting had BMI assessed and 11 patients were diagnosed as overweight/obese. Two of these 11 patients (18%) received weight loss advice.

The majority of patients had their medication regimen altered in both the Riverland hospital setting (96%) and GP clinic setting (97%). During the 12 month study period, a high percentage of patients were prescribed medications recommended for all patients with ACS. However, prescribing rates were as low as 42% for some recommended medications at the time of discharge from hospital (Table 3).

Prescribing rates at the time of hospital discharge in the current (Riverland) study were compared with 9 Australian and international studies (Table 4). Riverland prescribing rates for aspirin were similar to other studies. However, Riverland prescribing rate for beta blockers and ACE inhibitors were lower than most of the comparison studies. Prescribing rates for lipid lowering drugs varied widely between the comparison studies, with the Riverland having the sixth lowest rate.
Table 3: Recommended medications prescribed in the hospital setting \((n = 55)\) and GP clinic setting \((n = 34)\) during the 12 month study period

<table>
<thead>
<tr>
<th>Medication</th>
<th>Medication prescribed in hospital (%)</th>
<th>Medication prescribed in GP clinic (%)</th>
<th>Medication not prescribed (%)</th>
<th>No F/U in GP Clinic (no consent/ death) (%)</th>
<th>Prescribed medication during study (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin†</td>
<td>90</td>
<td>5</td>
<td>0</td>
<td>5</td>
<td>100</td>
</tr>
<tr>
<td>Clopidogrel†</td>
<td>64</td>
<td>4</td>
<td>14</td>
<td>18</td>
<td>86</td>
</tr>
<tr>
<td>Beta Blocker†</td>
<td>55</td>
<td>16</td>
<td>13</td>
<td>16</td>
<td>87</td>
</tr>
<tr>
<td>ACE inhibitor†</td>
<td>42</td>
<td>18</td>
<td>20</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>Statin§</td>
<td>66</td>
<td>20</td>
<td>4</td>
<td>10</td>
<td>96</td>
</tr>
<tr>
<td>Nitrates†</td>
<td>53</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td>80</td>
</tr>
</tbody>
</table>

F/U, Follow up.  
†Recommended for all patients unless contraindicated; §recommended for most patients unless contraindicated.

Table 4: Prescribing rates of recommended medications post acute coronary syndrome at the time of hospital discharge in the current (Riverland) study compared with 9 Australian and international studies\(^{20,22,23,25-30}\)

<table>
<thead>
<tr>
<th>Study</th>
<th>Location</th>
<th>Recommended ACS medications prescribed at hospital discharge %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Riverland 2004 – 2005 ((n = 55))</td>
<td>5 Rural hospitals Australia</td>
<td>Aspirin or antiplatelet drug - Clopidogrel 64 - Aspirin 90 - Beta Blocker 55 - ACE Inhibitor 42 - Lipid lowering drug 66</td>
</tr>
<tr>
<td>Acacia 2005 – 2006 ((n = 3402))</td>
<td>39 Metro, regional &amp; rural hospitals Australia</td>
<td>Aspirin or antiplatelet drug - Clopidogrel 82.7 - Aspirin 94 - Beta Blocker 81.9 - ACE Inhibitor 82.4 - Lipid lowering drug 92.9</td>
</tr>
<tr>
<td>Brisbane 2000 – 2001 ((n = 397))</td>
<td>3 Metro hospitals Australia</td>
<td>Aspirin or antiplatelet drug 94 - Clopidogrel - Aspirin - Beta Blocker 84 - ACE Inhibitor 73 - Lipid lowering drug 82</td>
</tr>
<tr>
<td>Queensland 1997 – 1998 ((n = 391))</td>
<td>1 Tertiary (T) &amp; 2 community (C) hospitals Australia</td>
<td>Aspirin or antiplatelet drug - Clopidogrel - Aspirin C 91 - Beta Blocker T 89 - ACE Inhibitor C 69 - Lipid lowering drug C 40</td>
</tr>
<tr>
<td>Tasmania 1998 ((n=71))</td>
<td>1 Metro hospital Australia</td>
<td>Aspirin or antiplatelet drug 90.3 - Clopidogrel - Aspirin 49.3 - Beta Blocker 59.2 - ACE Inhibitor 40.9</td>
</tr>
<tr>
<td>Symphony 1997 – 1999 ((n = 648))</td>
<td>37 Countries (Australia/ New Zealand stats displayed only)</td>
<td>Aspirin or antiplatelet drug - Clopidogrel - Aspirin 91 - Beta Blocker 75 - ACE Inhibitor 33 - Lipid lowering drug 44</td>
</tr>
<tr>
<td>Euroaspire II 1999 – 2000 ((n = 8181))</td>
<td>47 Hospitals in 15 European countries</td>
<td>Aspirin or antiplatelet drug 90 - Clopidogrel - Aspirin - Beta Blocker 66 - ACE Inhibitor 38 - Lipid lowering drug 43</td>
</tr>
<tr>
<td>Grace 2005 ((n = 26 413))</td>
<td>113 Hospitals in 14 countries</td>
<td>Aspirin or antiplatelet drug - Clopidogrel - Aspirin 95 - Beta Blocker 91 - ACE Inhibitor 77 - Lipid lowering drug 85</td>
</tr>
<tr>
<td>Crusade 2001 – 2003 ((n = 77 760))</td>
<td>457 Hospitals in the United States</td>
<td>Aspirin or antiplatelet drug - Clopidogrel 53.5 - Aspirin 89.7 - Beta Blocker 83.4 - ACE Inhibitor 60.6 - Lipid lowering drug 79.7</td>
</tr>
</tbody>
</table>
Table 4 (cont’d)

<table>
<thead>
<tr>
<th>Study</th>
<th>Location</th>
<th>Recommended ACS medications prescribed at hospital discharge %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dunedin</td>
<td>1 Hospital United Kingdom</td>
<td>Aspirin or antiplatelet drug Clopidogrel Aspirin Beta Blocker ACE Inhibitor Lipid lowering drug</td>
</tr>
<tr>
<td>2001 – 2002</td>
<td>(n = 577)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>98 80 55 70</td>
</tr>
</tbody>
</table>

ACS, Acute coronary syndrome.

Study citations: Riverland (current study), Acacia [25], Brisbane [26], Queensland [27], Tasmania [20], Symphony [28], Euroaspire ii [22], Grace [23], Crusade [29], Dunedin [30].

Discussion

Results of the current study indicate prescribing rates for ACS at the time of hospital discharge are suboptimal. However, overall prescribing rates in the 12 month period post-ACS are 80% or higher, suggesting a good level of guideline knowledge relating to pharmacological interventions. It is interesting to note the wide variation in hospital and GP clinic prescribing rates, despite the same GP usually overseeing patient care in both settings. Further investigation to determine the reason for this variation is warranted. Any intervention to increase the percentage of patients being prescribed recommended medications prior to discharge is likely to favorably affect patient outcomes. For example, 96% of patients were prescribed lipid lowering medication during the 12 month study period; however, only 66% were discharged from hospital on lipid medication. Increasing this prescribing rate could enhance patient outcomes, as intensive statin therapy initiated immediately after ACS has been shown to reduce recurrent cardiovascular events and mortality, and to improve the likelihood of patient adherence.

Increasing the use of recommended drug therapies, however, will not in itself raise the standard of secondary prevention of CVD. For secondary prevention to be successful, pharmacological interventions must be combined with the assessment of biomedical, and lifestyle and behavioural assessment and interventions to address identified risk factors. For example, blood lipid analysis is recommended for all patients with ACS. In the current study only 29% of patients were tested in the hospital setting. This finding is lower than previously reported testing levels internationally of 39%, 48% and 52.5%. It is interesting to note that a considerably higher number of patients who were transferred to a tertiary hospital underwent lipid analysis when compared with patients discharged home (42% vs 20%). This difference may be explained by the lower mean age of patients transferred to tertiary care (62 vs 80.5 years), as advanced age has been associated with lower rates of lipid testing. A significantly higher proportion of patients underwent lipid testing in the GP clinic setting (76%), again despite the same GP usually overseeing patient care from hospital to GP clinic.

Several other recommendations were poorly met, including tight glycaemic control in patients with diabetes, screening all patients for type 2 diabetes, and assessment and interventions for smoking and obesity/overweight. In addition, no patients were provided with the recommended written action plan for chest pain which includes explanations about rest, administration of recommended medications and calling for assistance. These care deficits may indicate the level of knowledge of clinical guidelines, or a lower importance placed on these interventions in comparison with other treatments. Often, when patients with chronic illness are admitted to an acute care setting, medical attention is focused on treating the acute problem rather than discharge planning and long-term care. Time constraints and inadequate staffing levels have also been cited as reasons for suboptimal assessment and intervention for biomedical risk factors. A combination of some or all of these factors may have led to the deficits identified in the current study. We would also argue that the absence of a structured approach to CR in the region contributed to these results.
Study limitations

The retrospective nature of this study relies on the accuracy and completeness of original documentation. Documentation of risk factor assessment and measurement in the current study was incomplete, and the possibility that interventions were offered but not documented must be considered when interpreting the findings. The use of non-probability sampling and the small sample size limits generalisability to the wider population. However, the findings have potential relevance to other rural areas with similar populations. It is important to note that this study did not examine the appropriateness of medication class, dosage or adherence rates and, therefore, no determination can be made regarding this. It also important to note that pharmacological interventions were assessed for a period of 12 months post AMI, and no determination can be made regarding long-term prescribing rates.

Conclusions

Unstructured secondary prevention interventions are currently provided to many rural and remote communities in the absence of a structured program. However the unstructured nature of these services means there is variability in the implementation of services and evaluation of outcomes. Consequently the efficacy of unstructured CR and subsequent patient outcomes is also variable. The results of this study provide a valuable insight into the level of unstructured secondary prevention provided by rural health services in the absence of a formal program. Our findings demonstrate that unstructured secondary prevention services can provide some of the recommended elements. Nevertheless, we identified several deficits in care that have the potential to negatively impact patient outcomes in this already disadvantaged population. Future research needs to focus on the extent to which rural and remote health care services are working within current clinical guidelines for the management of ACS, the appropriateness of prescribed medications, long-term prescribing rates, and subsequent patient outcomes.

There is strong evidence to support the efficacy of secondary prevention programs in relation to CVD related morbidity and mortality. In addition, secondary prevention is likely to be most beneficial in rural and remote settings where usual care may be less than optimal\cite{14,40}. Urgent consideration must, therefore, be given to the introduction and evaluation of a more structured and systematic approach in this and other rural and remote regions of Australia. The development of rehabilitation and prevention services that build on existing strengths and resources have the potential to widen access, enhance current services and ensure care is based on best practice guidelines. This, in turn, may reduce the burden of CVD and improve the overall health and quality of life for patients in rural and remote Australia.

References


33. Barclay L. Early, intensive statin use may improve outcomes in acute coronary syndrome. *Archives of Internal Medicine* 2006; 166: 1814-1821.


